Profender (5 - 8 kg)

2 x 1 pc

Spot-on, solution

Active substance

Praziquantel : 96 mg/pipette

Emodepside : 24 mg/pipette

ATC code

QP52AA51 Praziquantel, comb.

QP52AA Quinoline derivatives and related substances

QP52A Anthelmintics

QP52 Anthelmintics

QP Antiparasitic products, insecticides and repellents

Species

Cats.

Indications

For cats suffering from, or at risk from, mixed parasitic infections caused by roundworms, tapeworms and lungworms of the following species:

Roundworms (nematodes)

Toxocara cati (mature adult, immature adult, L4 and L3)

Toxocara cati (L3 larvae) - treatment of queens during late pregnancy to prevent lactogenic transmission to the offspring

Toxascaris leonina (mature adult, immature adult and L4)

Ancylostoma tubaeforme (mature adult, immature adult and L4)

Tapeworms (cestodes)

Dipylidium caninum (mature adult and immature adult)

Taenia taeniaeformis (adult)

Echinococcus multilocularis (adult)

Lungworms

Aelurostrongylus abstrusus (adult)

Dose to be administered and administration route

Spot-on use.

For external use only.

Dosage and treatment schedule

The recommended minimum doses are 3 mg emodepside / kg body weight and 12 mg praziquantel / kg body weight, equivalent to 0.14 ml of the veterinary medicinal product / kg body weight (bw).

Body weight of cat (kg)	Pipette size to be used	Volume (ml)	Emodepside (mg/kg bw)	Praziquantel (mg/kg bw)
≥ 0.5 - 2.5	Profender for small cats	0.35 (1 pipette)	3 - 15	12 - 60
> 2.5 - 5	Profender for medium cats	0.70 (1 pipette)	3 - 6	12 - 24
> 5 - 8	Profender for large cats	1.12 (1 pipette)	3 - 4.8	12 - 19.2
> 8	Use an appropriate combination of pipettes

For the treatment of roundworms and tapeworms a single administration per treatment is effective.

For the treatment of queens to prevent lactogenic transmission of Toxocara cati (L₃ larvae) to the offspring, a single administration per treatment approximately seven days prior to expected parturition is effective.

For the lungworm Aelurostrongylus abstrusus, two treatments administered two weeks apart are effective.

Method of administration

Remove one pipette from package. Hold pipette in upright position, twist and pull off cap and use the opposite end of the cap to break the seal.

Part the fur on the cat’s neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze firmly several times to empty the contents directly onto the skin. Application on the base of the skull will minimise the ability of the cat to lick the product off.

Underdosing could result in ineffective use and may favour resistance development

To ensure a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonably homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.

Adverse reactions

Cats:

Very rare

(< 1 animal / 10,000 animals treated, including isolated reports):

Neurological disorders^1,2,3 (ataxia^1,2,3, tremor^1,2,3)

Hypersalivation³, vomiting³, diarrhoea³

Application site alopecia², application site pruritus, application site inflammation

Behavioural disorders (hyperactivity, anxiety, vocalisation)

Anorexia, lethargy

¹ Mild

² Transient

³ These effects are thought to occur as a result of the cat licking the application site immediately after treatment

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.